| pubmed-article:18657673 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18657673 | lifeskim:mentions | umls-concept:C0018759 | lld:lifeskim |
| pubmed-article:18657673 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:18657673 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
| pubmed-article:18657673 | lifeskim:mentions | umls-concept:C0004238 | lld:lifeskim |
| pubmed-article:18657673 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:18657673 | lifeskim:mentions | umls-concept:C0205178 | lld:lifeskim |
| pubmed-article:18657673 | lifeskim:mentions | umls-concept:C0013778 | lld:lifeskim |
| pubmed-article:18657673 | lifeskim:mentions | umls-concept:C0206054 | lld:lifeskim |
| pubmed-article:18657673 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:18657673 | pubmed:dateCreated | 2008-7-28 | lld:pubmed |
| pubmed-article:18657673 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18657673 | pubmed:abstractText | Atrial fibrillation is the most common significant cardiac arrhythmia and substantially impacts the health status of patients. Enoxaparin has been shown to be a safe and effective alternative to unfractionated heparin for use with transesophageal echocardiography (TEE)-guided cardioversion, but the implications on health status remain unknown. The aim of the study was to compare the health status outcomes of patients who undergo TEE-guided cardioversion with enoxaparin or unfractionated heparin as anticoagulation bridging therapy. | lld:pubmed |
| pubmed-article:18657673 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18657673 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18657673 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:18657673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18657673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18657673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18657673 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18657673 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:18657673 | pubmed:issn | 1097-6744 | lld:pubmed |
| pubmed-article:18657673 | pubmed:author | pubmed-author:WeintraubWill... | lld:pubmed |
| pubmed-article:18657673 | pubmed:author | pubmed-author:KleinAllan... | lld:pubmed |
| pubmed-article:18657673 | pubmed:author | pubmed-author:ZhaoLipingL | lld:pubmed |
| pubmed-article:18657673 | pubmed:author | pubmed-author:JasperSusan... | lld:pubmed |
| pubmed-article:18657673 | pubmed:author | pubmed-author:LieberElizabe... | lld:pubmed |
| pubmed-article:18657673 | pubmed:author | pubmed-author:ElliottDaniel... | lld:pubmed |
| pubmed-article:18657673 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18657673 | pubmed:volume | 156 | lld:pubmed |
| pubmed-article:18657673 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18657673 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18657673 | pubmed:pagination | 374.e1-6 | lld:pubmed |
| pubmed-article:18657673 | pubmed:meshHeading | pubmed-meshheading:18657673... | lld:pubmed |
| pubmed-article:18657673 | pubmed:meshHeading | pubmed-meshheading:18657673... | lld:pubmed |
| pubmed-article:18657673 | pubmed:meshHeading | pubmed-meshheading:18657673... | lld:pubmed |
| pubmed-article:18657673 | pubmed:meshHeading | pubmed-meshheading:18657673... | lld:pubmed |
| pubmed-article:18657673 | pubmed:meshHeading | pubmed-meshheading:18657673... | lld:pubmed |
| pubmed-article:18657673 | pubmed:meshHeading | pubmed-meshheading:18657673... | lld:pubmed |
| pubmed-article:18657673 | pubmed:meshHeading | pubmed-meshheading:18657673... | lld:pubmed |
| pubmed-article:18657673 | pubmed:meshHeading | pubmed-meshheading:18657673... | lld:pubmed |
| pubmed-article:18657673 | pubmed:meshHeading | pubmed-meshheading:18657673... | lld:pubmed |
| pubmed-article:18657673 | pubmed:meshHeading | pubmed-meshheading:18657673... | lld:pubmed |
| pubmed-article:18657673 | pubmed:meshHeading | pubmed-meshheading:18657673... | lld:pubmed |
| pubmed-article:18657673 | pubmed:meshHeading | pubmed-meshheading:18657673... | lld:pubmed |
| pubmed-article:18657673 | pubmed:meshHeading | pubmed-meshheading:18657673... | lld:pubmed |
| pubmed-article:18657673 | pubmed:meshHeading | pubmed-meshheading:18657673... | lld:pubmed |
| pubmed-article:18657673 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18657673 | pubmed:articleTitle | Health status outcomes after cardioversion for atrial fibrillation: results from the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Trial. | lld:pubmed |
| pubmed-article:18657673 | pubmed:affiliation | University of Pennsylvania Division of General Internal Medicine, Philadelphia, PA, USA. eldaniel@mail.med.upenn.edu | lld:pubmed |
| pubmed-article:18657673 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18657673 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:18657673 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:18657673 | pubmed:publicationType | Multicenter Study | lld:pubmed |
